Prime Medicine Inc (PRME)

$3.09 -0.29 (-8.58%)
Market Cap 610.27M
Revenue (ttm) 4.63M
Net Income (ttm) -201.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,344.28%
Debt to Equity Ratio 0.00
Volume 1,968,823
Avg Vol 2,880,564
Day's Range N/A - N/A
Shares Out 180.55M
Stochastic %K 17%
Beta 2.56
Analysts Strong Sell
Price Target $6.92

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accum...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 465 0013
Address:
60 First Street, Cambridge, United States
El_Presidento
El_Presidento Mar. 30 at 7:10 PM
$PRME I’ve been waiting ages for some $2 PRME Let’s go 🕺🏻
0 · Reply
Windytimes
Windytimes Mar. 30 at 7:01 PM
$PRME down 31% since the Clinton’s deposition on Epstein and beginning of this pointless war.
0 · Reply
Windytimes
Windytimes Mar. 30 at 6:57 PM
$PRME man this sucks… hope the tide brings us back to shore one day
0 · Reply
StockMarketGuru
StockMarketGuru Mar. 30 at 6:47 PM
$PRME a bit concerning bere
1 · Reply
Elamenape2
Elamenape2 Mar. 30 at 5:48 PM
$PRME Reverse!
0 · Reply
srost002
srost002 Mar. 30 at 5:39 PM
$PRME so zero support. Nice.
0 · Reply
Montu11
Montu11 Mar. 30 at 5:22 PM
$PRME wow
0 · Reply
Grim123
Grim123 Mar. 30 at 5:22 PM
$PRME wow
0 · Reply
someguytrades
someguytrades Mar. 30 at 5:20 PM
$PRME scams getting washed out, smooth brains have bought prme with their scams, therefore prime gets washed out because algos think it’s scam like $OKLO $QBTS $IONQ $FRMI etc. Also probably getting margin called because the scams are down 70-80%
1 · Reply
arg195
arg195 Mar. 30 at 4:56 PM
$PRME maybe it's nothing
0 · Reply
Latest News on PRME
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 6, 2026, 5:25 PM EST - 23 days ago

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Mar 3, 2026, 8:00 AM EST - 27 days ago

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:00 AM EST - 4 weeks ago

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:16 PM EST - 2 months ago

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 2 months ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Dec 31, 2025, 1:29 PM EST - 3 months ago

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Dec 7, 2025, 8:05 AM EST - 4 months ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 4 months ago

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Nov 12, 2025, 2:51 PM EST - 4 months ago

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 8:00 AM EST - 4 months ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 10:21 AM EST - 5 months ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 5 months ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Nov 3, 2025, 8:01 AM EST - 5 months ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Oct 30, 2025, 4:01 PM EDT - 5 months ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 5:38 PM EDT - 7 months ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 7 months ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Aug 1, 2025, 4:01 PM EDT - 8 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 9:33 PM EDT - 8 months ago

Prime Medicine Announces Pricing of Public Offering

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 30, 2025, 4:01 PM EDT - 8 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 8:10 AM EDT - 9 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 16, 2025, 7:00 AM EDT - 9 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Jul 7, 2025, 4:45 PM EDT - 9 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:31 AM EDT - 11 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 19, 2025, 8:30 AM EDT - 11 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 11 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Jan 30, 2025, 12:26 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Nov 26, 2024, 5:10 AM EST - 1 year ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Prime Medicine Unveils Strategically Focused Pipeline

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet Bought Up Two Slumping Stocks

May 12, 2024, 3:00 AM EDT - 2 years ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

May 8, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 20, 2024, 4:01 PM EST - 2 years ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 11:50 PM EST - 2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 28, 2024, 8:11 AM EST - 2 years ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 25, 2024, 8:00 AM EST - 2 years ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 5, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

El_Presidento
El_Presidento Mar. 30 at 7:10 PM
$PRME I’ve been waiting ages for some $2 PRME Let’s go 🕺🏻
0 · Reply
Windytimes
Windytimes Mar. 30 at 7:01 PM
$PRME down 31% since the Clinton’s deposition on Epstein and beginning of this pointless war.
0 · Reply
Windytimes
Windytimes Mar. 30 at 6:57 PM
$PRME man this sucks… hope the tide brings us back to shore one day
0 · Reply
StockMarketGuru
StockMarketGuru Mar. 30 at 6:47 PM
$PRME a bit concerning bere
1 · Reply
Elamenape2
Elamenape2 Mar. 30 at 5:48 PM
$PRME Reverse!
0 · Reply
srost002
srost002 Mar. 30 at 5:39 PM
$PRME so zero support. Nice.
0 · Reply
Montu11
Montu11 Mar. 30 at 5:22 PM
$PRME wow
0 · Reply
Grim123
Grim123 Mar. 30 at 5:22 PM
$PRME wow
0 · Reply
someguytrades
someguytrades Mar. 30 at 5:20 PM
$PRME scams getting washed out, smooth brains have bought prme with their scams, therefore prime gets washed out because algos think it’s scam like $OKLO $QBTS $IONQ $FRMI etc. Also probably getting margin called because the scams are down 70-80%
1 · Reply
arg195
arg195 Mar. 30 at 4:56 PM
$PRME maybe it's nothing
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Mar. 30 at 3:47 PM
$PRME Daily Deion
0 · Reply
Elamenape2
Elamenape2 Mar. 30 at 2:50 PM
$PRME $BEAM
0 · Reply
DragonAlgo
DragonAlgo Mar. 30 at 8:44 AM
🐉 $PRME CALL — DragonAlgo® Signal Contract: PRME CALL Expiry: 2026-04-17 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.12 Stop: $0.09 TP1: $0.16 TP2: $0.20 TP3: $0.29 🔗 https://dragonalgo.com
0 · Reply
LadsAndGents
LadsAndGents Mar. 30 at 1:45 AM
$PRME bummer in last 2 days.. we all know destined to go double digits $SPY $XBI
0 · Reply
StockMarketGuru
StockMarketGuru Mar. 27 at 11:46 PM
$PRME they tricked us with that 3.80 yesterday
1 · Reply
shay7557
shay7557 Mar. 27 at 7:11 PM
$PRME Couldn't resist....bought 666 more.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Mar. 27 at 4:54 PM
AMERICA IS ON SALE MY TOP PICKS $ASTS $SLS $PRME $BA Coreweave, MP, CELH, OKLO Good luck all! Nfa
0 · Reply
someguytrades
someguytrades Mar. 27 at 3:15 PM
$PRME the retards are in control again
0 · Reply
arg195
arg195 Mar. 27 at 3:09 PM
$PRME there you go
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Mar. 27 at 2:43 PM
$PRME Daily Deion
0 · Reply
Montu11
Montu11 Mar. 26 at 6:27 PM
$PRME whoops… thought for a second there that we were actually going to see some progress here. My mistake
0 · Reply
PorkchopSquats
PorkchopSquats Mar. 26 at 3:46 PM
$PRME Plane just landed, hell yeah.
0 · Reply